Serroflo will substantially improve the affordability of fixed combinations in Europe and help manage health costs for respiratory treatment, the company said.
While the drug Salmeterol/Fluticasone MDI will be sold under the Serroflo brand in Germany, it will be marketed as Salmeterol/Fluticasone Cipla in Sweden, Cipla said in a statement.
Commenting on the development, Cipla Europe Head Frank Pieters said: "With Serroflo we offer in Germany and Sweden an alternative which is effective and efficient and therefore brings many advantages into a market which suffers from limited resources."
Also read: Logic behind big bang spike in pharma stocks
Serroflo will substantially improve the affordability of fixed combinations in Europe and help manage health costs for respiratory treatment, the company said.
The product will be available in the strengths of 120 doses of 25/125 mcg salmeterol/fluticasone and 120 doses of 25/250 mcg salmeterol/fluticasone, it added.
"Over the next 12-18 months we will see a series of launches throughout Europe as we know that there is a common need for high quality, affordable, reliable and thus sustainable therapy-alternatives ...," Cipla Managing Director and Global CEO Subhanu Saxena said.
In Europe, about 30 million patients under 45 years suffer from asthma causing a huge burden and triggering significant disability and work loss, Cipla said.
The introduction of Salmeterol/Fluticasone in Germany and Sweden is a key milestone in Cipla's ambition to improve treatment adherence in asthma and to offer better healthcare solutions for patients irrespective of what disease they suffer from, it added.
Cipla's portfolio includes 2,000 products in 65 therapeutic categories.
Cipla stock price
On August 22, 2014, Cipla closed at Rs 529.70, up Rs 15.40, or 2.99 percent. The 52-week high of the share was Rs 531.95 and the 52-week low was Rs 366.70.
The company's trailing 12-month (TTM) EPS was at Rs 15.51 per share as per the quarter ended June 2014. The stock's price-to-earnings (P/E) ratio was 34.15. The latest book value of the company is Rs 125.69 per share. At current value, the price-to-book value of the company is 4.21.
Anda sedang membaca artikel tentang
Cipla launches generic respiratory drug in Germany, Sweden
Dengan url
http://gayafashionshow.blogspot.com/2014/09/cipla-launches-generic-respiratory-drug.html
Anda boleh menyebar luaskannya atau mengcopy paste-nya
Cipla launches generic respiratory drug in Germany, Sweden
namun jangan lupa untuk meletakkan link
Cipla launches generic respiratory drug in Germany, Sweden
sebagai sumbernya
0 komentar:
Posting Komentar